NCT05854641View on ClinicalTrials.gov

Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Peripheral Arterial Disease

PHASE4RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

October 31, 2027

Study Completion Date

December 31, 2027

Conditions
Critical Limb IschemiaPeripheral Arterial Disease
Interventions
BIOLOGICAL

Stempeucel®

• Ex-vivo cultured allogeneic mesenchymal stem cells (MSCs) supplied in cryo-bags consisting of 150 or 200 million, suspended in 50 ml of Plasmalyte A containing 1.5% human serum albumin (HSA) and 3% dimethyl sulfoxide (DMSO).

Trial Locations (1)

56000

RECRUITING

Hospital Canselor Tunku Mukhriz, Kuala Lumpur

All Listed Sponsors
collaborator

Stempeutics Research Pvt Ltd

INDUSTRY

collaborator

National University of Malaysia

OTHER

lead

Cell Biopeutics Resources Sdn Bhd

INDUSTRY